The Risk of COVID-19 Pandemic in Patients with Moderate to Severe Plaque Psoriasis Receiving Systemic Treatments
Chronic plaque psoriasis is an inflammatory skin disease affecting 2–3% of the general population. Approximately one-third of patients are candidates for systemic immunosuppressive treatments, such as synthetic or biological disease-modifying antirheumatic drugs, because of disease extensions, local...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2020-12-01
|
| Series: | Vaccines |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2076-393X/8/4/728 |
| _version_ | 1827700886115188736 |
|---|---|
| author | Paolo Gisondi Francesco Bellinato Andrea Chiricozzi Giampiero Girolomoni |
| author_facet | Paolo Gisondi Francesco Bellinato Andrea Chiricozzi Giampiero Girolomoni |
| author_sort | Paolo Gisondi |
| collection | DOAJ |
| description | Chronic plaque psoriasis is an inflammatory skin disease affecting 2–3% of the general population. Approximately one-third of patients are candidates for systemic immunosuppressive treatments, such as synthetic or biological disease-modifying antirheumatic drugs, because of disease extensions, localization in sensitive or visible areas and/or resistance to topical treatments. These therapies have been associated with increased risk of infection, including upper respiratory tract viral infection. Psoriasis is frequently associated with cardio-metabolic comorbidities, such as obesity and diabetes, that are risk factors for poor prognosis in the case of coronavirus disease (COVID-19) pneumonia. A narrative review of the literature based on an electronic search of the PubMed<sup>®</sup> database was undertaken with the objective of investigating whether there is an increased risk of COVID-19 infection in psoriasis patients on systemic treatment. Original articles, such as case reports, published up to 1 November 2020 were included. There is no evidence that patients with moderate-to-severe psoriasis receiving systemic treatments, including biologics, have higher risk of SARS-CoV-2 infection and/or increased hospitalization and death related to COVID-19 compared to the general population. Several case reports described full recovery from COVID-19 with favorable outcomes in psoriasis patients who were being treated with synthetics or biologicals. Nonetheless, caution should be maintained in this setting, and more data are needed to draw definitive conclusions. |
| first_indexed | 2024-03-10T14:22:08Z |
| format | Article |
| id | doaj.art-2bca77a7462c46d2b5c9f1d20f90d519 |
| institution | Directory Open Access Journal |
| issn | 2076-393X |
| language | English |
| last_indexed | 2024-03-10T14:22:08Z |
| publishDate | 2020-12-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Vaccines |
| spelling | doaj.art-2bca77a7462c46d2b5c9f1d20f90d5192023-11-20T23:16:09ZengMDPI AGVaccines2076-393X2020-12-018472810.3390/vaccines8040728The Risk of COVID-19 Pandemic in Patients with Moderate to Severe Plaque Psoriasis Receiving Systemic TreatmentsPaolo Gisondi0Francesco Bellinato1Andrea Chiricozzi2Giampiero Girolomoni3Section of Dermatology and Venereology, Department of Medicine, University of Verona, 37126 Verona, ItalySection of Dermatology and Venereology, Department of Medicine, University of Verona, 37126 Verona, ItalyInstitute of Dermatology, Catholic University, 00185 Rome, ItalySection of Dermatology and Venereology, Department of Medicine, University of Verona, 37126 Verona, ItalyChronic plaque psoriasis is an inflammatory skin disease affecting 2–3% of the general population. Approximately one-third of patients are candidates for systemic immunosuppressive treatments, such as synthetic or biological disease-modifying antirheumatic drugs, because of disease extensions, localization in sensitive or visible areas and/or resistance to topical treatments. These therapies have been associated with increased risk of infection, including upper respiratory tract viral infection. Psoriasis is frequently associated with cardio-metabolic comorbidities, such as obesity and diabetes, that are risk factors for poor prognosis in the case of coronavirus disease (COVID-19) pneumonia. A narrative review of the literature based on an electronic search of the PubMed<sup>®</sup> database was undertaken with the objective of investigating whether there is an increased risk of COVID-19 infection in psoriasis patients on systemic treatment. Original articles, such as case reports, published up to 1 November 2020 were included. There is no evidence that patients with moderate-to-severe psoriasis receiving systemic treatments, including biologics, have higher risk of SARS-CoV-2 infection and/or increased hospitalization and death related to COVID-19 compared to the general population. Several case reports described full recovery from COVID-19 with favorable outcomes in psoriasis patients who were being treated with synthetics or biologicals. Nonetheless, caution should be maintained in this setting, and more data are needed to draw definitive conclusions.https://www.mdpi.com/2076-393X/8/4/728psoriasisSars-CoV-2COVID-19biologicssynthetic and biological disease-modifying antirheumatic drugs (DMARDs) |
| spellingShingle | Paolo Gisondi Francesco Bellinato Andrea Chiricozzi Giampiero Girolomoni The Risk of COVID-19 Pandemic in Patients with Moderate to Severe Plaque Psoriasis Receiving Systemic Treatments Vaccines psoriasis Sars-CoV-2 COVID-19 biologics synthetic and biological disease-modifying antirheumatic drugs (DMARDs) |
| title | The Risk of COVID-19 Pandemic in Patients with Moderate to Severe Plaque Psoriasis Receiving Systemic Treatments |
| title_full | The Risk of COVID-19 Pandemic in Patients with Moderate to Severe Plaque Psoriasis Receiving Systemic Treatments |
| title_fullStr | The Risk of COVID-19 Pandemic in Patients with Moderate to Severe Plaque Psoriasis Receiving Systemic Treatments |
| title_full_unstemmed | The Risk of COVID-19 Pandemic in Patients with Moderate to Severe Plaque Psoriasis Receiving Systemic Treatments |
| title_short | The Risk of COVID-19 Pandemic in Patients with Moderate to Severe Plaque Psoriasis Receiving Systemic Treatments |
| title_sort | risk of covid 19 pandemic in patients with moderate to severe plaque psoriasis receiving systemic treatments |
| topic | psoriasis Sars-CoV-2 COVID-19 biologics synthetic and biological disease-modifying antirheumatic drugs (DMARDs) |
| url | https://www.mdpi.com/2076-393X/8/4/728 |
| work_keys_str_mv | AT paologisondi theriskofcovid19pandemicinpatientswithmoderatetosevereplaquepsoriasisreceivingsystemictreatments AT francescobellinato theriskofcovid19pandemicinpatientswithmoderatetosevereplaquepsoriasisreceivingsystemictreatments AT andreachiricozzi theriskofcovid19pandemicinpatientswithmoderatetosevereplaquepsoriasisreceivingsystemictreatments AT giampierogirolomoni theriskofcovid19pandemicinpatientswithmoderatetosevereplaquepsoriasisreceivingsystemictreatments AT paologisondi riskofcovid19pandemicinpatientswithmoderatetosevereplaquepsoriasisreceivingsystemictreatments AT francescobellinato riskofcovid19pandemicinpatientswithmoderatetosevereplaquepsoriasisreceivingsystemictreatments AT andreachiricozzi riskofcovid19pandemicinpatientswithmoderatetosevereplaquepsoriasisreceivingsystemictreatments AT giampierogirolomoni riskofcovid19pandemicinpatientswithmoderatetosevereplaquepsoriasisreceivingsystemictreatments |